Skip to main content

Table 2 Univariate analysis for recurrence-free survival and overall survival

From: Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer

  OS RFS
P HR 95% CI P HR 95% CI
Age 0.099 1.524 0.924–2.512 0.622 1.123 0.708–1.781
Comorbidities
 CCI < 3 0.018 1.842 1.111–3.054 0.131 1.429 0.899–2.273
 CCI ≥3
Grade
 Well/Moderate 0.256 1.408 0.780–2.540 0.094 1.606 0.922–2.796
 Poor
Lymphovascular invasion 0.844 1.058 0.603–1.856 0.121 1.528 0.894–2.613
Perineural invasion 0.152 1.799 0.806–4.016 0.033 2.262 1.070–4.781
pT stage
 1–2 0.786 1.072 0.649–1.769 0.963 1.011 0.636–1.607
 3–4
Lymph node involvement 0.178 1.423 0.852–2.375 0.063 1.573 0.976–2.535
Pathologic stage
 I-II 0.588 1.150 0.694–1.907 0.495 1.175 0.739–1.868
 III-IV
Resection margin
 Negative 0.728 1.092 0.665–1.793 0.715 0.918 0.579–1.454
 Positive
Treatment
 Adjuvant CCRT 0.224 1.378 0.822–2.309 0.016 1.802 1.118–2.904
 Adjuvant chemotherapy
  1. OS Overall survival, RFS Recurrence-free survival, HR Hazard ratio, CCI Charlson comorbidity index, CCRT Concurrent chemoradiation therapy